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This article presents a review of the research literature to identify the methodology used and outcomemeasures
derived in the use of accelerometers tomeasure free-living activity in patientswith COPD. Using this and existing
empirical validity evidence we further identify standards for use, and recommended clinical outcome measures
from continuous accelerometer data to describe pertinent measures of sedentary behaviour and physical activity
in this and similar patient populations. We provide measures of the strength of evidence to support our recom-
mendations and identify areas requiring continued research. Our ﬁndings support the use of accelerometry in
clinical trials to understand andmeasure treatment-related changes in free-living physical activity and sedentary
behaviour in patient populations with limited activity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic, poorly re-
versible respiratory disease characterised by airﬂow limitation and dete-
rioration of lung function. According to The World Health Organisation,
COPD affects around 64 million people globally and killed more than 3
million people in 2004 [1]. The total annual cost of COPD to the UK Na-
tional Health Service is estimated to be over £800million [2]. Respiratory
symptoms of COPD include dyspnea, cough and production of sputum.
Difﬁculty breathing can causeCOPDpatients to have reduced ability to ex-
ercise and perform routine activity such as standing up and walking.
Physical activity reduces the risk of many chronic diseases through a
number of mechanisms including, for example, improved weight con-
trol, enhanced lipid proﬁles, improved glycaemic control and lower
blood pressure [3]. Psychological effects of physical activity include re-
ductions in stress, depression and anxiety [3]. Increased physical activi-
ty is also associated with improvements in quality of life [4]. In COPD,
inactive patients are reported to exhibit worse exercise capacity, more
dyspnea and a trend for worse functional statuswhich can lead patients
into a vicious cycle of increased dyspnea, exacerbations, deconditioning,
declining lung function and mortality [5,6]. Increasing physical activity
in COPD is associated with improved health outcomes including reduc-
tions in hospital admissions and respiratory mortality [7].
In clinical trials of COPD treatment, improvements in physical activ-
ity and mobility are important secondary outcomes and these are rou-
tinely estimated using in-clinic controlled assessments of exercise
capacity such as treadmill tests and the six minute walking test
(6MWT). In the 6MWT, the distance that a patient can walk in 6 min
is recorded, using either a treadmill or an empty corridor circuit. This
provides a controlled assessment of functional capacity [8]. For many
reasons, 6MWT distance may not always relate to the amount of phys-
ical activity and the degree of mobility that the patient actually achieves
in their daily living. For drug treatments that improve lung function in
COPD patients, increased activity and mobility and the associated
improvements in quality of life may be expected. This increased willing-
ness and motivation to conduct discretionary non-essential tasks requir-
ing levels of physical activity may be better measured in the home
context using an activity monitor.
Despite this, there has been limited usage of activity monitors to
measure physical activity endpoints in clinical drug development
programmes for COPDand related indications. Reasons for this are likely
due to a number of perceived barriers including: (i) regulatory accep-
tance of the validity of devices and the data management assumptions
made; (ii) scientiﬁc understanding of the data recorded and how to de-
rive meaningful summary outcome measures; and (iii) a lack of stan-
dards for implementing activity data collection in clinical trial protocols.
Research grade activity monitors retail from $200 to $300 per unit,
prices that are not prohibitive within the budget of many pharmaceuti-
cal clinical trials. Overall numbers requiredmay be reduced by recycling
and re-using devices within an individual study. The logistics associated
with device provision and management is a source of additional re-
source and expenditure when employing activity monitors in a global,
multicentre clinical trial.
1.1. Regulatory acceptance
Miniaturisation of sensors and circuitry has enabledhuge proliferation
in the development and commercialisation of wearable and external
monitoring devices in the areas of wellness and health. Examples include
cardiac and ECG monitoring devices and sleep and activity monitors. Ac-
tivity monitors and their associated apps and software are growing in
popularity for those wanting to improve ﬁtness or manage weight
through regular exercise regimens. High accuracy and precision of these
devices is less important in the personal health monitoring arena, yet
vital in the area of clinical research if the data from these devices are to
be used in the accurate characterisation of treatment related effects [9].
Not all commercial devicesmayhave thedegree of accuracy andprecision
that would warrant their use in clinical trials, but some manufacturers
have invested signiﬁcantly into the scientiﬁc validation of their devices
and associated algorithms, and validation evidence has been published
in peer reviewed journals. This provides good evidence of device validity,
accuracy and precision that can support the use of such devices in clinical
trials. This may be associated with European CEmarking approval and/or
US 510(k) approval as additional device quality credentials.
In addition to the ability of the device to accurately measure activity
andmobility in terms of continuously recorded accelerometer data, reg-
ulators will be concernedwith how the recorded data were cleaned and
summarised, what assumptions were made in doing so, and the rele-
vance of the outcome measures derived.
A growing number of commercial devices provide the raw
accelerometry data, but all summarise raw signals into counts and/or
estimates of energy expenditure such as METs and kcals. Firmware on
the device is responsible for translating raw accelerations into these
summary measures, and activity intensity thresholds (e.g. moderate,
vigorous) and energy expenditure is then determined with reference
to published doubly labelledwater calibration curves or VO2/HR regres-
sion lines. Usually the speciﬁc details of the preliminary data processing
algorithms are contained within the device and proprietary to the de-
vice manufacturer and not disclosed. This ﬁrmware is also responsible
for ﬁltering noise out of the signal — for example routine vibrations
picked up as small accelerations duringmotor vehicle travel. The extent
of published validation work should provide a measure of conﬁdence in
the scientiﬁc validity of this ﬁrmware, although a growing number of
accelerometers are beginning to provide access to the rawdata enabling
researchers to apply standard open algorithms to interpret the
accelerometry signals.
Aside from this, regulators will have an interest in how valid data is
identiﬁed amongst the continuous streamof data recorded. This will in-
clude, for example, reviewing the assumptions thatweremade to deter-
mine whether a period where no activity was recorded was due to lack
of movement or due to removal of the device, and how missing data
were dealt with — arising, for example, from periods of non-wear
during a day, or missing days of data.
1.2. Scientiﬁc understanding of the data
Activity monitors provide a variety of variables associated with ac-
tivity. For pedometers, the most basic measure is the number of steps
over a period of time. The equivalent for accelerometers is the number
of counts, which measure not just the presence of a movement but
also the magnitude of force (acceleration) generated by movement. As
indicated above, activitymonitors also often use these to estimate ener-
gy expenditure in the form of kcals and METs.
There aremany differentways inwhich continuous activity data can
be summarised to create relevant summary statistics. As opposed to
total counts/steps or total energy expenditure, increased mobility in
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somepatient groupsmay be better shown in the duration of bouts of gen-
tle activity, such aswalking. The total counts per daymay not be sensitive
to detecting these sorts of subtle changes, butmeasures such as the num-
ber of times a patient walked, the duration of walking achieved, and the
number of walking episodes exceeding a deﬁned duration (e.g. 60 s)
may bemore sensitive to detecting change and improvement [9]. The ob-
jective here is perhaps to identify discretionary activity as opposed to
more involuntary functional activity, such as going to the bathroom.
In healthier subjects, total counts per day may be a useful measure,
but there are also other valuable summary measures that may be sensi-
tive indicators of change in activity, in particular the time spent in differ-
ent levels of exertion, such as moderate physical activity and vigorous
physical activity. Cut-points can be deﬁned that relate to different inten-
sities of activity. Using these, time spent at different exercise intensities,
such as light, moderate, vigorous and very vigorous activity, can be cal-
culated. Again, in certain situations, these may provide a more sensitive
measure of increased ﬁtness or activity than a measure of total activity
or energy expenditure over the day.
In addition, the overall effect of sedentary behaviour on health
outcomes is thought to be independent of the degree of moderate and
vigorous activity achieved during active periods [10], and therefore
characterisation of sedentary behaviour may also be an important
health outcome measure.
For application in clinical trials it will be important to carefully con-
sider and deﬁne a priori the summary outcomemeasures that should be
calculated. These should be selected based on knowledge of the patient
population andhow improvements and changes inmobility and activity
might be observed. Those designing clinical development programmes
will beneﬁt from published studies identifying outcome measures that
are sensitive to detecting treatment-related improvements in the pa-
tient population of interest.
1.3. Standards for implementation
As described previously, a possible barrier to large scale use of activ-
ity monitors in clinical trials is a lack of consensus in implementation
standards. Standards, for example, apply to the type of device used,
the location of the device on the patient's body and the number of
days of measurement required for reliable estimation of overall activity.
For example, when it comes to sensor location, common locations
include wrist, arm, waist, thigh and foot. Some locations may be chosen
with consideration of patient convenience and maximising wear time
(e.g. wrist), whereas other locations may be selected for more scientiﬁc
reasons. For example, thigh placement may provide more robust infor-
mation on whether the patient is standing or seated, whereas the waist
may be less well suited to identify postural changes but may enable
optimal estimation of energy expenditure associated with walking
activity [11].
This article reviews the research literature to understand how activ-
ity monitors have been used in COPD research studies to date. The
objective was to identify learnings that may help to guide standards
for their use in future research and to help to limit the perceived
barriers in large scale implementation in regulatory clinical devel-
opment programmes.
2. Methods
Eighty-nine research studies published between 1999 and 2014
were identiﬁed through a PubMed search in January 2015 for published
articles containing both “COPD” and “Activity” in the article title and/or
abstract; with additionally at least one of the following search terms:
“Pedometer”, “Accelerometer” and “Accelerometry”. The list was subse-
quently reduced to 76 studies [12–87] after review articles (n = 2),
clinic-only investigations (n = 5), algorithm development and valida-
tion studies (n=1), studies not using an activitymonitor (n=1), stud-
ies not investigating COPD subjects (n = 1), and foreign language
articles without an English translation available (n= 3) were removed.
Of the 76 studies, our review contained 42 cross-sectional studies, 18 in-
tervention studies (either using an activity monitor as a component of
an intervention or tomeasure the impact or an intervention), 3 longitu-
dinal studies and 13 measurement studies (e.g. assessing the measure-
ment qualities of the activity measure).
The methodology used in each of the 76 studies was summarised
(Table 1) and included in the review to understand methods used and
outcomes measured when utilising an activity monitor with COPD
patients. Where the article did not provide information on a speciﬁc
aspect, this was recorded as “not reported”.
The full metadata description of all studies included in this review is
available on request from the ﬁrst author.
3. Results
3.1. Activity monitor: model
The most commonly used activity monitors reported by the sample
of COPD research studies were as follows (Fig. 1a):
• The SenseWear Armband device (BodyMedia Inc., Pittsburgh, PA), 11
out of 76 studies, a triaxial accelerometer worn on the arm using a re-
movable armband.
• The DynaPort Activity Monitor (McRoberts BV, Netherlands), 11 out
of 76 studies, a triaxial accelerometer usually worn on a belt around
the waist around the lower back.
• The ActiGraph 7164, GT1M and GT3X+ devices (ActiGraph, Pensaco-
la, FL), 7 out of 76 studies. The 7164 is a uniaxial accelerometer, the
GT1M is a biaxial accelerometer, and the GT3X+ is a triaxial acceler-
ometer, all usually worn on the waist, although the GT3X+ is also
commonly worn on the wrist.
• The RT3 Tracker (StayHealthy Inc., Monrovia, CA), 7 out of 76 studies,
a triaxial accelerometer usually worn at the waist.
• The Yamax Digiwalker (Yamax Corporation, Tokyo, Japan), 6 out of 76
studies, a step-counting pedometer worn at the waist.
Table 1
Features of activity monitor use reviewed in the sample of studies.
Area of
consideration
Feature/aspect reviewed Primary categories
Activity
monitor
Model Device manufacturer and model
Placement location • Number of sensors
• Sensor location(s)
Data collection Period of wear • Requested days wear time
• Weekend/weekday wear
requirements
• Overnight wear
Number of hours wear for
a valid day
Number of hours
Data
management
Number of valid days
required
• Number of valid days required
• Rules for exclusion of days
(e.g. Hawthorne effect)
Deﬁnition of a non-wear
episode
• Wear sensors or ﬁrmware
algorithms
• Non-wear rules based on activity
data
Missing data
methodology
Missing data rules and assumptions
Data analysis Summary endpoints
analysed
• Total activity measure
• Time in bouts of activity
• Body position
• Postural transitions
• Time inactive/active
• Intensity of activity
• Daily temporal activity proﬁle
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• The StepWatch 3 Activity Monitor (Orthocare Innovations LLC, Seattle,WA), 5 out of 76
studies, an ankle-worn step-counting pedometer.
The “Other” category contained 22 different activity monitor models
each reported once or twice across the sample of articles. One study did
not report themodel of activitymonitor used. At the time of this review,
a number of activity monitor device models reported have been super-
seded by new versions. In many of these cases the newmodels contain
fundamentally the same components and ﬁrmware, although some
may be associated with performance differences.
3.2. Activity monitor: placement location
Over 40% of studies (31/76) used an activity monitor attached to
a belt around the waist and located at the waist or hip (Fig. 1b).
Some authors determined that monitors should be located on a
speciﬁc side of the body, sometimes specifying the non-dominant
side although the rationale for the choice of side was not given.
On some occasions it was reported that patients were instructed
to wear the device in line with the thigh midline. Eleven studies
(14%) provided activity monitors that were attached to the arm
using an armband. Again, some authors determined that a speciﬁc
arm was to be used. Ankle attachment was reported by 8% (6/76)
and wrist by 4% (3/76) of studies. Multiple locations were used in
seven studies where more than one sensor was used, for example
hip and arm locations or waist and thigh locations. Single studies
also reported housing activity monitors in the trouser pocket of
the patient or on the patient's shoe, and two studies at the lower
back.
Fig. 1. Summary of activity monitor, data collection and data management methodologies reported in the sample of studies.
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3.3. Data collection: period of wear
Huge variation in the number of days subjects were instructed to
wear an activity monitor was observed across the sample of studies
(Fig. 1c). However, there were little differences in prescribed wear
time based on the study type — the median wear time was 7 days for
cross-sectional, intervention and measurement studies. Of the six stud-
ies requiring activity monitor wear for greater than 30 days, two were
longitudinal studies examining changes in physical activity around the
time of exacerbation [31,78], and for this reason required longer wear
periods of 16 weeks and 6 months respectively. Two were intervention
studieswhere the activitymonitorwas a component of the intervention
[21,55] with 90 day and 14 week wear periods respectively. One study
[75] used activity monitors to measure the impact of an exercise
counselling programme over a 12 week period, and a further study
[43] was a clinical trial of the β2-agonist, indacterol, requiring activity
monitor wear for an 8 week period.
Inmany studies, subjectswore the device for a deﬁned period before
or at the start of an intervention or observation period, and then repeat-
ed this later to enable within-subject estimation of changes in activity.
The length of period of wear varied from a 2 day period (8 of 76 studies)
to 6 months continuous wear (reported by a single study). The mean
wear periodwas 15.6 days (sd=29.0 days), with amedianwear period
of 7 days (interquartile range: 5 to 9 days). Most commonly, 7 days was
selected as the required wear interval (36%, 27 of 76 studies), with
3 days (7 out of 76 studies) and 2 weeks (7 out of 76 studies) the next
most commonly reported intervals. There were no reported compliance
ﬁgures accompanying reports and so it was not possible to understand
the impact of wear interval on subjects' willingness and ability to con-
tinue wearing the device, although it is assumed that this must have
been a challenge for the studies collecting data for multiple weeks. A
small number of studiesmeasuring less than seven days of activity spec-
iﬁed whether the assessment interval was required to contain one or
more weekend days. One study of seven days assessment required the
device to be worn overnight on one occasion during the assessment
week [80].
3.4. Data collection: valid day deﬁnition
Themajority of studies did not report how a valid day of devicewear
was determined (36 of 76 studies, Fig. 1d). It is not clear in these cases
whether some data were excluded or all data included in the reported
analysis, whether data were standardised across patients to allow for
missing intervals, or whether some assumptions and imputations
were made to allow for missing data. Of studies that did report deﬁni-
tions of a valid wear day, the majority of studies identiﬁed a minimum
of 10 or 12 hour wear time to constitute a valid day (12 and 11 studies
respectively). The mean valid day deﬁnition was 12.8 h (sd = 5.6 h),
with a median of 10 h (interquartile range: 9.9 to 12 h). Two studies in-
cluded in the valid day category of 10 h ormore deﬁned the valid day as
9.8 h or more (70% of the interval 08:00 to 22:00 h). Seven studies (9%)
reported 8 h to be theminimum required, and 5 studies (6.5%) expected
a full 24 hour period to be collected for inclusion in their analysis. One
study reported that all data were included independent of wear time
achieved [70].
3.5. Data management: number of valid days required
While requested to wear an activity monitor for a deﬁned wear pe-
riod, some authors felt that if a minimum number of days wear was
achievedwithin this interval, then this would provide an adequate esti-
mation of the general pattern of activity of the patient. Over two thirds
of authors did not report the minimum number of days required (53
of 76 studies, 70%, Fig. 1e). Of those that did report the minimum
number of valid days needed this ranged from a minimum of 2 to
7 valid days, with some authors requiring the valid interval to
include one or both weekend days. One study [63] excluded the
ﬁrst and last days of their 7 day measurement interval routinely
due to the device being provided and returned on these days
resulting in incomplete measurement on these days. A further
study of 10 days of activity monitor use, examined only the last
7 day period to eliminate reactivity (Hawthorne effect) and to en-
sure every day of the week was included [73].
3.6. Data management: deﬁnition of non-wear episode
Themajority of articles did not report how non-wear timewas iden-
tiﬁed (67 of 76 studies, 88%, Fig. 1f). Four studies identiﬁed a 60 minute
period of zero counts as evidence of the device not being worn. One of
these studies allowed up to two one-minute epochs to register counts
less than 100 amongst the 60 min zero count episode to also qualify
as non-wear time, likely to allow for the device being moved or the
presence of spontaneous electrical spikes whilst not worn. One study
used a 20 min or more period of zero counts as non-wear time [60].
Two studies used more complex deﬁnitions of non-wear. In one study
[71], the RT3 Tracker (StayHealthy Inc., Monrovia, CA) was assumed to
be worn at a speciﬁc point in time if at least two of the following condi-
tions based on VectorMagnitude Units (VMU, ameasure of acceleration
in the direction of travel, calculated as the square root of the sum of the
squared accelerations in the three orthogonal directions measured)
were satisﬁed:
1. Is VMU·min−1 value N5?
2. Of the following 20min, do at least two haveVMU·min−1 values N5?
3. Of the preceding 20min, do at least two have VMU·min−1 values N5?
A further study using the StepWatch Pedometer (Orthocare Innova-
tions LLC, Seattle, WA) considered non-wear days as opposed to inter-
vals within a day — deﬁning a non-wear day as a day with fewer than
200 steps recorded over a minimum of 8 h [40]. Two studies [34,77],
using the Dynaport (McRoberts BV, Netherlands) and SenseWear arm-
bands (BodyMedia Inc., Pittsburgh, PA) respectively, reported non-
wear as estimated automatically by the device ﬁrmware, but did not
provide the deﬁnition used. A further study used patient diary records
to indicate periods of non-wear [67].
3.7. Data management: missing data methodology
No studies reported methodologies for dealing with missing data
aside from the deﬁnitions of valid days and valid intervals as described
above. In all cases, it seems that patients with insufﬁcient data, or days
with insufﬁcient recording intervals, were excluded from the analyses.
By eliminating data in this way, non-biased estimates of overall activity
could still be obtained ifmissingdataweremissing truly at random. This
may be the case if non-wear (for example) is due solely to forgetfulness
as opposed to other reasons such as participating in water-based activ-
ities or periods of poor health, but without additional contextual infor-
mation this is not possible to determine.
3.8. Data analysis: summary endpoints analysed
The types of summary endpoints reported could be categorised into
seven broad measurement categories (Table 2) and discussed below.
Before summarising the activity data recorded, one study adjusted
the time spent travelling in a motor vehicle with average VMUs whilst
sitting based on self-reported travel times from a patient diary [86].
3.8.1. Total activity
Over two thirds of the studies reviewed (69.7%) reported one or
more measure of overall daily activity. In all studies, total activity was
expressed as the daily number of steps or accelerometer counts or
VMUs. Accelerometer counts are a measure of the frequency and inten-
sity accelerations and decelerations in the vertical axis. Counts are units
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whose values are speciﬁc to each brand of monitor. One study reported
total counts recorded across a two day period. Some studies also report-
ed overall activity in MET hours (5 of 76 studies). METs are “metabolic
equivalents” deﬁned as the energy cost of physical activities as a multi-
ple of the resting metabolic rate— represented by a value of 1.0. One of
these studies compared the time spent at a number of different ranges
of MET values between treatment groups [43]. Approximately 12% of
studies reported estimates of energy expenditure when summarising
overall activity. The majority of these (7 of 9 studies) reported total
daily energy expenditure in kcal. Single studies reported the total
daily intensity of activity (MET·h) in bouts of activity above a deﬁned
MET threshold — either 1.4 METs [58] or 3.0 METs [76]. A further
study reported the total distance walked per day [45].
3.8.2. Time in bouts of activity
Approximately 40% of studies (30 of 76 studies) reported a measure
of time spent in deﬁned intensities of physical activity. Activity level
thresholds were based on steps, METs or counts per minute, VMUs or
(in fewer studies) walking speed. Some cut-off points for activity levels
were in line with the scientiﬁc literature. For example, cut-off points
based on counts reported by validation studies performed by Freedson
reported sedentary, light and “lifestyle” activity as b100, 100–759 and
760–1951 counts per minute respectively [88], based on device-
speciﬁc counts thresholds from the vertical axis of the ActiGraph
(ActiGraph, Pensacola, FL) device. Most frequently, activity levels were
deﬁned based upon METs (around 13% of studies). Because METs indi-
cate the increase in energy expenditure during an activity relative to
the patient's resting energy expenditure, some authors consider them
to be themost suitable energy expenditure unit to be used [89]. General
intensity thresholds based onMETs have been reported as 3–6METs for
moderate activity, 6–9 METs for vigorous, and N9 METs for very vigor-
ous [90]. Tudor-Locke and Rowe [91] identify METs as the measure for
which there is greatest consensus in the literature for use in determin-
ing activity intensity thresholds. Importantly, they also identify that
the relationship between walking speed, or cadence, and METs to be
relatively consistent between individuals of varying ﬁtness levels.
While these thresholds were used by some studies to deﬁne the time
spent in different levels of physical activity, other studies used different
cut-off points and did not report a rationale for their selection. In one
study [44] cut-off points usedwere based on themeanmaximal oxygen
uptake during a separate cardiopulmonary incremental exercise test in
the same group of patients. The authors felt this approachwas advanta-
geous in comparison to previous research in COPDwhere standard cut-
off points for the general populationwere used, as they suggest that this
results in higher relative intensities when applied to older less ﬁt
individuals.
Table 2
Summary endpoints derived and reported in the sample of studies.
Endpoint (units/time period reported) Number of
studies
reported (%)
Total activity 53 (69.7%)
Number of steps (per day/per hour) 38 (50.0%)
Number of counts (per day/per hour) 12 (15.8%)
VMUs (per day) 3 (3.9%)
MET·h or MET·min 5 (6.6%)
Energy expenditure (kcal) 7 (9.2%)
Energy expenditure during activity N1.4 METs 1 (1.3%)
Energy expenditure during activity N3 METs 1 (1.3%)
Distance walked (per day) 1 (1.3%)
Time in bouts of activity (min/%) 30 (39.5%)
Based on steps: High intensity (N80 steps/min) 2 (2.6%)
Based on steps: Medium intensity (31–80 steps/min) 2 (2.6%)
Based on steps: Low intensity (≤30 steps/min) 1 (1.3%)
Based on METs: Sedentary (1–1.9 METs) 1 (1.3%)
Based on METs: Light (2–2.9 METs) 1 (1.3%)
Based on METs: Mild (≥2.4 METs) 1 (1.3%)
Based on METs: Moderate (≥3.6 METs) 1 (1.3%)
Based on METs: Moderate (3–6 METs) 5 (6.6%)
Based on METs: Vigorous (N6 METs) 7 (9.2%)
Based on METs: Activity b3 METs 3 (3.9%)
Based on METs: Activity ≥3.5 METs 1 (1.3%)
Based on METs: Activity ≥3.4 METs 1 (1.3%)
Based on METs: Activity ≥3 METs 10 (13.2%)
Based on METs: Activity ≥2.6 METs 1 (1.3%)
Based on METs: Activity ≥2.5 METs 2 (2.6%)
Based on METs: Activity ≥2 METs 2 (2.6%)
Based on METs: Activity ≥1.5 METs 1 (1.3%)
Based on walking speed: Speed b2 km/h 1 (1.3%)
Based on walking speed: Speed ≥2 km/h 1 (1.3%)
Based on walking speed: Moderate/intense walking (N3.5 km/h) 1 (1.3%)
Based on walking speed: Speed N5 km/h 2 (2.6%)
Based on counts: sedentary (b100 cpm) 4 (5.3%)
Based on counts: Activity (≥100 cpm) 1 (1.3%)
Based on counts: Lifestyle active level (100–759 cpm) 1 (1.3%)
Based on counts: Light physical activity (100–1951 cpm) 2 (2.6%)
Based on counts: counts N1951 cpm 2 (2.6%)
Based on counts: Light physical activity (100–2019 cpm) 2 (2.6%)
Based on counts: Moderate physical activity (2020–4944 cpm) 1 (1.3%)
Based on counts: MVPA (N2020 cpm) 1 (1.3%)
Based on counts: MVPA (N760 cpm) 1 (1.3%)
Based on counts: Vigorous physical activity (N4944 cpm) 1 (1.3%)
Based on counts: VMUs N 250 cpm 1 (1.3%)
Based on counts: VMUs N 500 cpm 1 (1.3%)
Based on counts: VMUs ≤ 3000 cpm 1 (1.3%)
Based on counts: VMUs N 3000 cpm 2 (2.6%)
Body position and modes activity 15 (19.7%)
Time spent standing 6 (7.9%)
Time spent lying 7 (9.2%)
Time spent sitting 9 (11.8%)
Time spent walking 12 (15.8%)
Time spent moving but not walking 1 (1.3%)
% day spent lying or sitting 1 (1.3%)
Maximum bout time: lying 1 (1.3%)
Maximum bout time: sitting 1 (1.3%)
Maximum bout time: standing 1 (1.3%)
Maximum bout time: walking 1 (1.3%)
Postural transitions 1 (1.3%)
Number of postural transitions per day 1 (1.3%)
Number of postural transitions: standing from lying 1 (1.3%)
Number of postural transitions: standing from sitting 1 (1.3%)
Time inactive/active 7 (9.2%)
Time inactive: based on steps (0 steps/min) 2 (2.6%)
Time active 5 (6.6%)
Intensity of activity 20 (26.3%)
Peak performance (maximum steps per 1-minute epoch) 2 (2.6%)
Mean max 30 (mean steps of the highest 30 1-minute epochs) 1 (1.3%)
PAL: Physical Activity Level (total energy expenditure/resting
energy expenditure)
9 (11.8%)
PAL N 1.7 (yes/no) 1 (1.3%)
Average movement intensity during walking (g) 3 (3.9%)
Average walking intensity (m/s) 1 (1.3%)
Number of MVPA bouts of at least 10 min
(MVPA: counts N 760 cpm)
1 (1.3%)
Mean MVPA bout duration (MVPA: counts N 760 cpm) 1 (1.3%)
Table 2 (continued)
Endpoint (units/time period reported) Number of
studies
reported (%)
Mean intensity of MVPA bouts (cpm) (MVPA: counts N 760 cpm) 1 (1.3%)
Number of bouts of at least 10 min and N= 1.5 METs 1 (1.3%)
Mean duration of bouts of at least 10 min and ≥1.5 METs 1 (1.3%)
Mean intensity (METs) of bouts of at least 10 min ≥ 1.5 METs 1 (1.3%)
Number of bouts of at least 10 min and ≥2.6 METs 1 (1.3%)
Mean duration of bouts of at least 10 min and ≥2.6 METs 1 (1.3%)
Mean intensity (METs) of bouts of at least 10 min ≥ 2.6 METs 1 (1.3%)
Number of bouts of at least 10 min and ≥3.4 METs 1 (1.3%)
Mean duration of bouts of at least 10 min and ≥3.4 METs 1 (1.3%)
Mean intensity (METs) of bouts of at least 10 min ≥ 3.4 METs 1 (1.3%)
Maximal METs 1 (1.3%)
MVPA recommendation achieved (Y/N) 1 (1.3%)
Mean activity intensity (total counts/wear time) 6 (7.9%)
Daily activity proﬁle 2 (2.6%)
Proﬁle of counts per hour over the day 2 (2.6%)
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3.8.3. Body positions and modes of activity
The time spent in different body positions and associated activity
was reported in 19.7% of studies reviewed. Most commonly examined
was time spent walking, standing, sitting and lying (12, 6, 9, and 7 stud-
ies respectively). Single studies also reported the percentage of the day
spent lying or sitting [17], and time spent moving but not walking [45].
One study also reported the maximum time spent lying, sitting, stand-
ing and walking in any single period/bout in that state [32]. While re-
ported by the ﬁrmware within many accelerometers, it is unclear how
accurately sitting, standing and lying states can be identiﬁed, in particu-
lar by thoseworn on thewaist, wrist, armor ankle, aswas the case in the
majority of studies in this review. In these positions, the spatial position-
ing of the accelerometer may not change signiﬁcantly between sitting
and standing states. In addition to the cut-off points described above,
time spent sitting or lying is a further measure of sedentary behaviour.
3.8.4. Postural transitions
One study using an accelerometer with sensors on the thigh and
chest explored the number of times COPD patients changed posture —
either standing up from seated or standing from lying down [32].
While multi-sensor devices facilitate this kind of investigation, most re-
searchers use commercially available instruments which generally
comprise single sensors. Currently, the standard device for measuring
postural transitions, the ActivPAL (PAL Technologies, Glasgow, UK),
distinguishes standing from sitting or lying and work is in progress to
differentiate between sitting and lying (Douglas Maxwell, PAL Technolo-
gies, personal communication). Postural change is an interesting outcome
measure that may be sensitive to detecting changes in discretionary non-
routine daily activity in activity-compromised patients, and one that is
seeing increased use in public health research. For example, Carlson
et al. [92] identiﬁed that increasing postural transitions by including an
additional 10 breaks in sedentary bouts per day resulted in a systematic
improvement in waist circumference, blood pressure, HDL, triglycerides,
fasting glucose and insulin in adults.
3.8.5. Time inactive/active
Seven studies (9.2%) looked at the time spent active over the day,
and two studies reported the time spent inactive (based on intervals
of zero steps). The studies reporting time inactive based on intervals
of zero activity did not provide a deﬁnition of non-wear time and it is
unclear whether inactive time may be overestimated by including
periods of non-wear.
3.8.6. Intensity of activity
Twenty studies (26.3%) reported some form of outcomes measuring
the intensity of activity achieved. Almost half of these reported the daily
physical activity level (PAL) which was calculated as the total daily en-
ergy expenditure divided by the resting energy expenditure (9 studies).
In some cases, resting energy expenditure was estimated by sleeping
energy expenditure as patients were instructed to wear the activity
monitor for the full 24 hour period (e.g. [14]), or by estimation using
gender-speciﬁc Harrison and Benedict prediction equations [93]. One
study examined whether a target PAL of greater than 1.7 was achieved
[77]. The International Association for the Study of Obesity recommends
a PAL score of 1.7 or above to represent an amount of daily activity suf-
ﬁcient to prevent the transition to overweight or obesity [94].
Six studies derived the mean activity intensity by dividing total
counts by wear time, providing an estimate of counts per hour. Three
studies also considered the average movement intensity during walk-
ing, measured in g, and one in average metres per second. Two studies
reported peak performance, deﬁned as the maximum number of steps
achieved in a single 1 minute epoch [53,68]. One of these studies also
derived a similar summary statistic, “mean max 30”, deﬁned as the
mean number of steps achieved across the 30 1-minute epochs record-
ing the highest step counts [53]. This has parallels with the concept of
peak stepping cadence developed by Tudor-Locke and Rowe [95].
Single studies also summarised activity intensity by considering the
intensity during bouts of moderate and vigorous physical activity
(MVPA). In one study [51], rather than reporting the total time in
MVPA, outcomemeasures included the number of MVPA bouts exceed-
ing 10 min in duration, the mean bout duration and the mean intensity
of bouts (counts per minute). This study also examined the proportion
of patients achieving the physical activity recommendations of the
Centres for Disease Control and Prevention, the American College of
Sports Medicine [96], and the British Association of Sport and Exercise
Sciences [97] that existed at the time. These required at least 150 min
per week of MVPA (counted in bouts exceeding 10 min). A second
study examined the number, duration and intensity of activity bouts
exceeding 10 min above thresholds of 1.5, 2.6 and 3.4 METs [58].
3.8.7. Daily activity proﬁle
Two studies explored the proﬁle of activity across the day. One study
[47] examined the average daily activity proﬁle curves of COPD subjects
compared to controls, and also analysed the activity recorded in three
segments of the day: morning (8:00 h to 13:00 h), afternoon (13:00 h
to 17:00 h), and evening (17:00 h to 20:00 h). A second study [71] eval-
uated individual activity-time proﬁles by deriving average 24 hour
time-proﬁles for each subject. Thesewere calculated by taking the activ-
ity observed within each hour of the day and averaging this across all of
the days observed. Perhaps fundamental in deriving these average pro-
ﬁles is an assumption that certain activities, and periods of inactivity,
regularly occur at a similar times of day.
4. Discussion and recommendations
Large scale implementation of activitymonitors in regulatory clinical
trials requires accepted and consistent methodology for how these
wearables are used and how the data they generate is interpreted.
Usage standards andmethods are likely to vary according to the patient
population, disease indication and perceived treatment beneﬁts. This
review of activity monitor use with COPD patients has shown little con-
sensus andmuch variability in many of themethodology areas we have
identiﬁed as important in clinical trial implementation. While consen-
sus can be derived in some areas of methodology, weweigh this against
a more detailed consideration of the limitations imposed by the disease
along with other key works in activity measurement. We propose stan-
dards and the rationale behind our recommendations, and include with
each a measure of conﬁdence in our recommendations based on the
strength of associated scientiﬁc evidence found in our review or else-
where in the scientiﬁc literature (Table 3). This level of conﬁdence is
summarised using a red, amber or green categorisation. A green classi-
ﬁcation represents high conﬁdence in the recommendations based on
the high consensus in our review and/or strong scientiﬁc evidence else-
where. Amber classiﬁcation represents, in our opinion, a reasoned ap-
proach where a number of different alternatives have been reported.
Where we have classiﬁed an item as red, we propose that the recom-
mendation has merit but that more research and evaluation is needed
to provide a standard for future research.
Tudor-Locke et al. in their evaluation of activity in special popula-
tions [98] found activity levels amongst COPD patients to be one of the
lowest amongst the groups they studied. Median steps per day were
2237 steps/day in COPD studies compared to 8008 steps/day amongst
subjects with type 1 diabetes. Similarly, Walz et al. [77] demonstrated
that few patients in each category of COPD severity (GOLD I–IV) record-
ed a PAL exceeding 1.7, implying sedentary activity levels across all
levels of disease severity. Treatment-related improvements in lung
function may directly relate to increased willingness and motivation
to participate in recommended exercise regimens, and in particular
reduce the quantity of sedentary behaviour and its impact. Aerobic
exercise (riding an exercise bicycle or walking) and resistance exercise
(lifting lightweightswith the arms and legs) can help restore andmain-
tain functional independence in COPD. The American College of Sports
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Medicine (ACSM) supports the viewpoint that light to moderate physi-
cal activity (30 min a day, on most, if not all days of the week) is bene-
ﬁcial for improving the quality of life in persons with COPD [99].
More recently, it has been shown that sedentary behaviour and
moderate and vigorous physical activity are independently related to
functional ﬁtness (see for example [10, 100–102]). In essence, periods
of sedentary behaviour have a negative impact on functional ﬁtness
even when periods of activity and exercise are undertaken. This has
associated impact with chronic disease progression and risk factors. It
would seem appropriate that characterisation of sedentary behaviour in
addition to physical activity is important in most cases, and perhaps par-
ticularly so in indications such as COPD where barriers to exercise exist.
The above suggests that in COPD, measuring changes in sedentary
behaviour, and the daily time spent in light or moderate activity may
be important elements to considerwhen assessing treatment related ef-
fects and associated improvements in quality of life.
Table 3
Proposed standards for activity measurement in COPD clinical trials.
Methodology item Proposed approach Rationale Conﬁdence in
recommendationa
Activity monitor type Preferred: a triaxial accelerometer with access to raw data.
Accepted: a triaxial accelerometer without access to raw data
with sufﬁcient storage capacity for at least 7 days data
captured in 15 s epochs.
A triaxial accelerometer enables activity and may enable
postural changes to be measured.
Raw data enables retrospective application of different epoch
intervals if required.
Green
Activity monitor
placement
Preferred: thigh
Accepted: waist (if attachment options will not inﬂuence
device-compliance and wear time).
Thigh placement enables accurate assessment of sedentary and
postural transitions.
Wrist placement has high wear-compliance but less validation
evidence for identifying postural transitions, although this is an
area being actively addressed, and no validation evidence for
determination of sedentary periods.
Green
Epoch length Record with, or process into, 15 s epochs. Older studies tend to use 60 s due to historical limitations on
data storage.
Newer devices and post-hoc analyses of raw data enable
shorter epoch lengths to be easily used. Shorter epoch lengths
are recommended for estimation of sedentary behaviour, and
we consider less than 15 s to provide little additional value.
Green
Number of days worn 7 days To achieve at least 5 days of valid data from a 7 day wear
interval.
Amber
Number of hours wear for
a valid day
10 h or more 10 h is most commonly reported in the literature in this
population and likely to be a practical time period to encourage
reasonable wear compliance. However, thigh placement under
a waterproof dressing (e.g. ActivPAL device) enables 24 hour
wear to be easily collected.
Amber
Valid interval deﬁnition
(number of valid days)
5+ days (no requirement for speciﬁc numbers of weekend or
week days)
Five days is reported to be sufﬁcient to describe overall activity
in less active populations. Weekend vs. weekday effect not
likely to be a factor in this population.
Amber
Deﬁnition of non-wear
episode
60 min of zero counts with up to two 1-minute epochs of up
to 100 cpm for ActiGraph, or equivalent for other devices
Literature consensus. Green
Missing data
methodology
Eliminate non-valid days and participants without sufﬁcient
valid days.
It is assumed that subjects providing the minimum number of
valid days provide sufﬁcient data to provide reliable estimates
of daily activity. Less than this amount of data does not provide
sufﬁcient information for robust estimation of overall activity.
We do not recommend modelling or other imputation
methods for subjects with an insufﬁcient number of valid days
as this approach has not been validated in this population.
Without contextual information explaining the reason for
missing values the best unbiased approach to missing data
estimation cannot be determined.
Green
Summary endpoints
analysed
Sedentary behaviour Due to the level of activity expected in the patient population,
treatment related effects on overall activity are most likely to
be seen ﬁrst in changes in sedentary behaviour and
light/moderate activity.
• Total sedentary time per day (standardised to a 16 hour
wear interval)
Amber
• Maximum sedentary bout length per day Red
• Number of postural transitions (lying/sitting to standing/-
walking) per day (standardised to a 16 hour wear interval)
Red
Light/moderate activity Our proposed measures of time in physical activity based on
cadence of 60 steps/min or greater for minimum intervals of 2 min
and 5 min are intended to measure periods of time in rhythmic,
continuous ambulatory activity as opposed to sporadic pottering
activity. This threshold is an achievable cadence for COPD patients
even at more advanced stages of the disease, based on 6MWT data.
We identify two bout intervals as the duration of 5minmay not be
achievable by all patients, this longer bout measuring greater
endurance in patients with higher ﬁtness levels. The associated
metabolic stimulus of this form of exercise is different to pottering
behaviour and important for cardiovascular health as opposed to
functional activity.
Total steps and cadence (steps/min), unlike counts, are common
across instruments, interpretable and easily related to programme
goals.
• Number of walking episodes of at least 1 minute duration
per day
Amber
• Mean walking episode length Amber
• Maximum walking bout length per day Red
• Mean walking cadence (steps/min) Red
• Time in physical activity (cadence ≥60 steps/min for a min-
imum interval of 2 min and a minimum interval of 5 min)
Red
Overall activity
• Total steps per day Green
a Green: high conﬁdence in the recommendations based on the high consensus in our review and/or elsewhere; amber: a reasoned approachwhere a number of different alternatives
have been reported; red: recommendation has merit but more research and evaluation is needed to provide a standard for future research.
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4.1. Measuring changes in sedentary behaviour
There are a number of considerations regarding the measurement
and characterisation of sedentary behaviour. Epoch length, for example,
has been shown to affect the estimation of total sedentary time. Atkin
et al. [103] reported that studies exploring epoch length for measure-
ment of sedentary time are inconsistent in their conclusion, but in gen-
eral a shorter epoch length is recommended. Accelerometers providing
raw data summarise the data into epochs using the device software and
enable different epoch lengths to be applied post hoc.
A key component of measuring sedentary time is understanding
posture. Some authors conclude that devices measuring only activity
and not providing reliable posture information may be less accurate in
measuring sedentary behaviour than devices able tomeasure both com-
ponents [104]. For example, time spent standing still is not sedentary,
although valuable in health in breaking sedentary behaviour, whereas
time spent sitting or lying is sedentary. In addition, sleeping is not gen-
erally detrimental to health and therefore should not be classed as sed-
entary behaviour. It is therefore important to be able to distinguish time
spent sleeping fromwakeful lying down, although doing so reliablymay
be out of scope of current activity monitor algorithms. Where measure-
ment of sedentary behaviour and treatment related changes is impor-
tant, a monitor positioned on the thigh is of greatest value as this can
most effectively determine sedentary postures from the inclination of
the thigh in addition to activity performed. Recent ongoing algorithm
development work for ActivPAL, a thigh-positioned accelerometer,
may also help to distinguish lying from sitting, and to some extent
wakeful lying from sleeping lying, due to other thigh movements char-
acteristic in each posture — such as thigh rolling when lying (Douglas
Maxwell, ActivPAL, personal communication).
Few devices support convenient thigh placement, but the ActivPAL
is a device that has been developed speciﬁcally for this with the objec-
tive of measuring sedentary behaviour and postural changes. This de-
vice, about the size and shape of an SD card, is attached to the thigh of
the patient within a nitrile sleeve and beneath a waterproof dressing
(e.g. Tegaderm™ transparent dressing) which provides permanent
and waterproof attachment for 7 days which is the recommendation
of this article. This kind of permanent attachment has the additional ad-
vantage that it enables the full 24 hour period to be studied without
wear/non-wear compliance considerations. This approach is generally
well accepted by patients, with a small number reporting skin irritation
associated with the dressing and requiring its replacement to maintain
the required recording period.
Determining clinically relevant measures of sedentary behaviour
from the rich stream of accelerometer data recorded is an area of
current research. Ideally, one or more derived measures should assess
both the total amount of sedentary time and the length of bouts or the
degree to which sedentary periods are broken up by changes in posture
or periods of activity. Additionally, sleep time should be determined in
order to differentiate this from wakeful lying.
There remains uncertainty about how to characterise clinically rele-
vant periods of sedentary behaviour. For example:
a) How long does sitting have to continue in order to constitute a clin-
ically relevant bout of sitting?
b) How long does standing/walking have to continue to constitute a
clinically relevant “break in sitting”?
c) Does the answer to question b) dependon the answer to question a),
and vice versa? For example, if a subject sits for 20 min but breaks
this by standing for 5 s, does this constitute two 10-minute bouts
of sitting, with one meaningful break, or one 20-minute bout of
sitting, with an inconsequential standing event in the middle?
Understanding the answer to these questions is the focus of active
research. Some authors have proposed summary measures to measure
sedentary behaviour. Tieges et al. [105], for example, recommend
three summary statistics to measure sedentary behaviour from activity
monitor data:
1. Total sedentary time (h/d).
2. Weighted median sedentary bout length - the length of the sedentary
bout that corresponds to 50% of accumulated sedentary time. For ex-
ample, if 10 h of sedentary time is recorded for a particular day, this
measure would represent the length of the bout that contains the
5 hour time-point when bouts are ordered cumulatively from smallest
to largest.
3. Fragmentation Index — the ratio of the number of sedentary bouts
divided by total sedentary time for each individual.
Tieges et al. describe the Fragmentation Index as a single summary
measure describing the pattern of accumulation of sedentary time,
where a higher Fragmentation Index indicates that total sedentary
time is accumulated from a higher number of shorter bouts rather
than a few prolonged periods. This index is calculated in the same
way as the Sleep Fragmentation Index that is used to assess sleep arous-
al in sleep studies using the number of arousals and total sleep time.
The latter two measures proposed by Tieges et al. show potential
promise in that they attempt to summarise both the total sedentary
time and the number of bouts or bout length into single indices. Howev-
er,more needs to be understood about the properties of thesemeasures,
for example when calculating the weighted median how much data
(how many bouts) is needed to generate reliable estimates for each
subject? In addition, summary statistics need to be related to health out-
comes and be sensitive to enable detection of changes associatedwith im-
proved or worsening of those outcomes. The proposed Fragmentation
Index, for example, would return the same value of 1.0 for a subject
with a single one-hour bout of sedentary behaviour and a second subject
with 10 bouts of 1 h. It would seem likely that these scenarios would be
associated with different health outcomes. In addition, as the Fragmenta-
tion Index is the inverse of themean bout length, it is likely to bewell cor-
related with the median bout length and total sedentary time measures
proposed and so may offer little additional value. More research will be
required to determine the most clinically relevant sedentary measures.
Based onwhat is currently known about summarymeasures for sed-
entary behaviour, we suggest that the total sedentary time, the maxi-
mum sedentary bout, and the number of postural transitions from
sitting/lying to standing/walking are of value to characterise changes
in sedentary activity and capture changes in discretionary activity. It is
acknowledged, however, that more research is needed to better under-
stand the speciﬁc properties of sedentary behaviour that relate to di-
minished health outcomes (such as the time of day of sedentary
periods, the length of sedentary periods, the number of breaks in seden-
tary behaviour and theminimumbeneﬁcial break length). This will lead
to a greater ability to identify the most clinically relevant measures to
describe sedentary behaviour and its impact on health.
Sleep quality is affected in COPD which may lead to daytime sleepi-
ness and daytimenapping and extended periods ofwakeful lying. As de-
scribed above, napping does not have the same detrimental effects as
being seated or lying while awake and so it may become increasingly
important to be able to measure sleeping episodes, both nocturnal and
during the day, alongside activity and posture information to accurately
characterise sedentary behaviour. Because daytime napping occurs in
COPD, standard time algorithms, or daily logs to determine bedtime
and morning wake-time, are likely to be insufﬁcient in this population.
4.2. Measuring light/moderate and overall activity
In a potentially very sedentary population, measures such as overall
activity expressed as daily counts, energy expended, or time spent being
active may be less sensitive to detection of small but important changes
in mobility. Quality of life improvements may be achieved frommodest
short discretionary activities that a subject elects to perform in addition
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to required functional activities performed out of necessity, such as get-
ting up to walk to the bathroom.
People with short strides or a shufﬂing gait, seen in some COPD sub-
jects, have less vertical displacement of their centre of gravity while
walking, making it more likely that pedometers or waist-mounted ac-
celerometers may underestimate steps or activity [106]. However, the
volume of research studies examined did not identify this as a limitation
of using accelerometry in this patient population.
As described previously, COPD patients are recommended to follow
an exercise schedule that may consist of aerobic exercise and resistance
activity. We recommend that in addition to the overall number of
counts per day, researchers investigating activity changes in COPD clin-
ical trials also explore the number and duration of walking episodes.
Thought should be given to the ability to detect the difference between
cycling and stepping if some patients elect to use an exercise bicycle to
follow their aerobic recommendations. Early validation work to distin-
guish between cycling and stepping has been performed, for example
using the ActivPAL [107], and further algorithm development work is
anticipated to enable greater precision in determining different forms
of exercise. We propose that calculation of the number of walking
episodes per day, the mean and maximum walking bout length, and
mean walking cadence are sensible measures of light and moderate ac-
tivity in these patients.
In line with The American College of Sports Medicine recommenda-
tions of 30 min of light to moderate activity per day for COPD patients,
we additionally propose that the length of time per day in bouts of at
least light physical activity (LPA) is important. Our review found a
large variation in the deﬁnition of cut-points for different intensity cat-
egories and their interpretation. Count thresholds are device-speciﬁc
and researchers need to refer to validation studies on speciﬁc devices
to determine the appropriate count cut-points to deﬁne LPA. For
Actigraph (Pensacola, FL) devices, 100 cpm appears a common thresh-
old to deﬁne the transition point from sedentary behaviour to light
activity in our review, although a recent study has proposed 150 cpm
as a least biased estimate of the sedentary/light activity threshold,
although this is based on a small sample of subjects [108]. While accel-
eration measures, such as counts, provide sophisticated measures of
both the presence and magnitude of activity, counts have less direct in-
terpretability. While not reported in the studies we reviewed, we pro-
pose intensity thresholds based on cadence to provide understandable
and interpretable measures that can be easily adapted into guidance
and targets, and are well correlated with other intensity threshold
measures [95]. To distinguish between sporadic pottering activity and
a period of sustained rhythmic, continuous, purposeful ambulatory
movement we propose two cadence bout thresholds of 60 steps/min
for at least 2 min and 60 steps/min for at least 5 min. The cadence
threshold of 60 steps/min is reasonable for patients with COPD, based
on published evidence in controlled walk tests. For example, Annegarn
et al. [109] reported cadences in excess of 100 steps/min during a
6MWT for patients at all stages of COPD. Similarly, in three other studies
[110–112], participants with COPD completed the 6MWT at speeds typ-
ically corresponding to cadences over 100 steps/min (based on prior ev-
idence of the speed/cadence relationship [91]). We identify two bout
intervals as the duration of 5 min may not be achievable by all patients,
this longer bout measuring greater endurance in patients with higher
ﬁtness levels. In the study reported by Annegarn et al. [109], for exam-
ple, 15% of patients were unable to complete the 6-minute test without
resting. A further study [113] similarly showed that 4/7 patients rested
during a 6MWT, some for more than 1 min. We recommend additional
research to determinewhether one or both bout durationmeasures are
most useful in this population. These measures represent a sustained
period of stepping as opposed to a simple step accumulation target as
differentiated by Stansﬁeld et al. [114]. The associated metabolic stimu-
lus of this form of sustained exercise is different to pottering and short
breaks in sedentary behaviour, and is important for cardiovascular
health as opposed to functional activity. This period of sustained
stepping is also likely to indicate an excursion out of the house, which
is associated with quality of life components. Accelerometers to mea-
sure steps and cadence must provide accurate step counting and
time-stamped stepping data such as steps per minute or time spent
above speciﬁed stepping rates. Tudor-Locke and Rowe [95] summarise
the accuracy and ability of a number of commercial devices to do this,
and many common commercial accelerometers provide suitable sensi-
tivity including the ActivPAL and Actigraph devices.
4.3. Period of wear, valid day and number of valid days needed
Themost common period of wear reported in the articles within this
review was 7 days. This is an intuitively logical choice as it captures
weekdays and weekend days. Hart et al. [115] estimated that 5 days of
measurement in older adults is sufﬁcient to enable representative
measurement of physical activity and sedentary behaviour in older
adults. As described above, COPD patients are amongst the least active
of many special populations, and it would seem reasonable that the rec-
ommendations of Hart and colleagues would be relevant to apply here.
While activity onweekends, or non-workingdays, can be quite different
to that of working days in some populations (see [9] for example), in
more compromised patient populations there may be less ability to
work and the difference between weekdays and weekend days may
not be relevant. We conclude that a measurement interval of at least
ﬁve days evaluable data, with no requirement to measure a speciﬁc
number of weekend or weekday days, would be acceptable in COPD
subjects.
While it is desirable to use a device that is not removed by the
patient, and thus records the full 24 hour interval; where this is not pos-
sible, we feel the consensus of a minimumof 10 hour wear time per day
may not be sufﬁcient to accurately characterise activity and mobility.
Herrmann et al. [116] used datasets from theNational Health andNutri-
tion Examination Survey (NHANES, [117]) to explore the impact ofwear
time on activity estimates. Their examination of data from around 4000
individuals concluded that using 12 h or less wear data signiﬁcantly re-
duced estimates of time spent in activity and sedentary behaviour and
may potentially affect estimates of individuals meeting activity recom-
mendations. They concluded using more than 12 h of activity data per
day ensures accurate estimates of daily physical activity. For certain
devices this may represent a compliance concern and an impractical
approach that would result in insufﬁcient evaluable data. For example,
Tucker [118] reported wear compliance of a waist-worn accelerometer
using NHANES data as 18% for 7 ormore days with at least 12 h per day;
versus 33% for at least 10 h a day. However, if sedentary behaviour is
measured, as we recommend for this population, a thigh-basedmonitor
is optimal and these can be conveniently afﬁxed to the body for the full
24 hour period under a discreetwaterproof dressing as described for the
ActivPAL device above.
Kang and Rowe [119] estimated the time spent in different physical
behaviours based on aggregated data from a number of studies
in adults, using data from NHANES. They identiﬁed that on average
0.4–3.0% of time over a 24-hour period is spent in MVPA, 27–41%
is spent in LPA, 31–39% is spent in sedentary behaviour and 28–
31% in sleep. As LPA and sedentary time accounts for so much of
the overall 24 hour period, obtaining accurate estimates of the daily
time spent in these states may require a lengthier sampling interval.
Obtaining a reliable estimate of daily sedentary and LPA times, however,
may be achievable using a shorter sampling interval and adjusting for
the period of wear – for example, estimating the proportion of wear
time that accounts for sedentary behaviour, or standardising the seden-
tary time measured to a standard waking day of 16 h.
4.4. Deﬁnition of wear and non-wear
Accurate identiﬁcation of non-wear episodes is an important con-
sideration in accurate measurement of sedentary time. It is possible
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thatwhile assuming that a period of zero counts represents non-wear, it
may be possible to wrongly associate a period of sedentary time with a
non-wear episode. Ideally, deviceswithwear sensors or devices that are
adhered to the body (e.g. ActivPAL) may eliminate this potential
challenge.
Most non-wrist-worn devices do not contain skin sensors to deter-
mine accurately when devices were worn and removed. For this reason,
assumptions regarding the length of time that a device recording no ac-
tivity should constitute a period of non-wear need to be made. Where
reported, 60min of zero counts was the most common, with the allow-
ance of two one-minute epochs with non-zero counts not exceeding a
certain device-speciﬁc threshold (e.g. 100 cpm for the ActiGraph de-
vice) appropriate to allow for the device being moved whilst not worn
or for random electrical disturbance. Studies in children consider
shorter intervals as evidence of non-wear due to the level of movement
expected in younger individuals.
4.5. Validation of endpoints for clinical drug licencing submissions
Activity data measured using an activity monitor falls into the Per-
formance Outcomes (PerfO) category of Clinical Outcome Assessments
(COAs). It will be required by the Pharmaceutical Company (Sponsor)
to provide an evidence dossier to support the use of the activitymonitor
in the patient population studied. This will include supporting evidence
of the device's measurement properties to show that the device is able
to accurately measure the construct of interest (for example activity,
posture etc.). Generally this will be obtained from the literature,
where some devices have been subject to published robust validation
studies in a variety of patient populations to demonstrate the validity,
accuracy and precision of the device measurement and ﬁrmware algo-
rithms. Sponsors should select a device with sufﬁcient validation evi-
dence to satisfy this requirement.
It will also be required of the sponsor that derived endpoints
summarising the activity data are clinically meaningful in the target
population. It is less likely that this information can be obtained directly
from a manufacturer in all cases, but over time the use of certain sum-
mary endpoints in published studies may provide a starting point.
Most likely, data using activity monitors during phase II of the drug de-
velopment process will be useful in demonstrating that the summary
endpoints derived are clinically meaningful, for example that they cor-
respond to other treatment related improvements and quality of life
changes.
5. Conclusions
In this article we suggest that the widespread use of activity moni-
tors in pharmaceutical clinical trials may be limited by uncertainties
over regulatory requirements concerning the validity of devices and
the data management assumptions made (such as deﬁnitions of valid
days), the clinical relevance and validity of derived summary outcome
measures, and a lack of agreed standards for implementing activity
data collection in clinical trial protocols.
While not the focus of this article, we recommend that devices se-
lected for use in clinical trials should be conﬁned to those for which
there is a body of validation evidence published by researchers and/or
device manufacturers.
In terms of data management assumptions, the development of
meaningful derived summary outcomemeasures, and standards for im-
plementation, while the research literature contains many examples of
the use of activity monitors in COPD studies, the research community
have yet to converge on a set of standard methodologies, despite their
value in measuring important health outcomes for pharmaceutical clin-
ical trials. This article serves to summarise current practise and provide
recommendations based on the research literature for a set of imple-
mentation and data management standards, and a set of pertinent de-
rived health outcome measures considered important in describing
changes in activity in this patient group. Throughout the recommended
standards, areas where additional research is needed to provide more
deﬁnitive conclusions is identiﬁed.
These proposed standardsmay help to drive the use of activitymon-
itors in measurement of free-living activity in COPD clinical drug devel-
opment programmes, and may have application beyond COPD and
apply equally to other disease indications characterised by low intensity
of physical activity and high degrees of sedentary behaviour.
Appendix A. supplementary data
The full metadata description of all studies included in this article
can be found online at http://dx.doi.org/10.1016/j.cct.2016.01.006.
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